RGS16 promotes glioma progression and serves as a prognostic factor. (22nd April 2020)

• Record Type: Journal Article
• Authors: Huang, Ruoyu; Li, Guanzhang; Zhao, Zheng; Zeng, Fan; Zhang, Kenan; Liu, Yanwei; Wang, Kuanyu; Hu, Huimin
• Is Part Of: CNS neuroscience & therapeutics. Volume 26:Number 8(2020)
• Page Start: 791
• Page End: 803
• Publication Date: 2020-04-22
• Subjects: EMT -- glioma -- immune response -- prognosis -- RGS16; Neuropharmacology -- Periodicals; Central nervous system -- Diseases -- Effect of drugs on -- Periodicals; 612.8
• DOI: 10.1111/cns.13382
• Languages: English
• ISSNs: 1755-5930

Abstract

Abstract: Background: RGS protein family members have recently became new potentially promising therapeutic targets in many cancers. However, as a key member of RGS family, RGS16 has seldom been studied in glioma. The present study was designed to investigate the prognostic value and biological function of RGS16 based on large‐scale databases and functional assays in vitro. Methods: Here, we performed comprehensive analysis for the expression characteristic of RGS16 in Chinese Glioma Genome Atlas (CGGA) microarray database with 301 patients and validated in The Cancer Genome Atlas (TCGA) microarray and RNA sequencing database. Student's t‐test, one‐way ANOVA test and long‐rank test were used to assess differences between groups. Kaplan‐Meier survival, univariate and multivariate Cox analysis and ROC curve were used to estimate the survival distributions. Biological implication of abnormal expression of RGS16 in glioma was also explored. Functional analysis of RGS16 was performed in several glioblastoma (GBM) cell lines. R language and SPSS were used for statistical analysis and graphical work. Results: We found that the expression of RGS16 was positively related to the grade of glioma. High level of RGS16 commonly gathered in glioma of mesenchymal subtype and wild‐type IDH1. Moreover, higher expression level of RGS16 was found to be significantly correlated with poor prognosis. The univariate and multivariate Cox regression analysis and ROC curve showed that RGS16 was an independent prognostic factor for glioma patients. Gene ontology analysis, gene set enrichment analysis, and gene set variation analysis suggested that the overexpression of RGS16 tightly related to cell proliferation, migration, epithelial‐mesenchymal transition (EMT), immune and inflammatory response of glioma. Knockdown of RGS16 in glioma cell lines also showed that RGS16 promoted the malignant progress of glioma cell lines. Conclusions: RGS16 plays an important role in glioma progression and serves as an independent prognostic factor, especially in GBM patients.